468 Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial
Thomas Hatschek(Karolinska University Hospital), Martina Sundqvist(University of Gothenburg), Zakaria Einbeigi(Sahlgrenska University Hospital), Lena Carlsson(University of Gothenburg), Thomas Walz(Rockefeller University), Martin Malmberg(Skåne University Hospital), B. Linderholm(Reykjavík University), Birgitta Lindh(Uppsala University Hospital), Niklas Loman(Lund University), Martin Söderberg(Uppsala University Hospital)
Cited by 1
Related Papers
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Bariatric Surgery and Long-term Cardiovascular Events
|JAMA|2012|1.6k